Page 19 - 《中国药科大学学报》2025年第4期

第 56 卷第 4 期 贾佳庆，等：核酸模式识别机制及其化学干预的研究进展 415

reported-outcomes defined clinical endpoints in patients with ul- 2012, 23(3): 275-280.
cerative colitis[J]. Dig Liver Dis, 2018, 50(10): 1019-1029. [59] Maelfait J, Rehwinkel J. The Z-nucleic acid sensor ZBP1 in
[52] Pant S, Wainberg ZA, Weekes CD, et al. Lymph-node-targeted, health and disease[J]. J Exp Med, 2023, 220(8): e20221156.
mKRAS-specific amphiphile vaccine in pancreatic and colorec- [60] Subbarao Malireddi RK, Kesavardhana S, Kanneganti TD.
tal cancer: the phase 1 AMPLIFY-201 trial[J]. Nat Med, 2024, ZBP1 and TAK1: master regulators of NLRP3
30(2): 531-542. inflammasome/pyroptosis, apoptosis, and necroptosis (PAN-op-
[53] Henry JT, Pavlick AC, Humphries T, et al. Abstract CT045: a tosis)[J]. Front Cell Infect Microbiol, 2019, 9: 406.
phase 1/2 trial of TAC-001 (TLR9 agonist-CD22 MAb) in ad- [61] Mishra S, Dey AA, Kesavardhana S. Z-nucleic acid sensing and
vanced or metastatic solid tumors[J]. Cancer Res, 2025, activation of ZBP1 in cellular physiology and disease pathogen-
85(8_Supplement_2): CT045. esis[J]. Immunol Rev, 2025, 329(1): e13437.
[54] Lee GH, Lim SG. CpG-adjuvanted hepatitis B vaccine (HEP- [62] Nakahama T, Kawahara Y. The RNA-editing enzyme ADAR1:
LISAV-B®) update[J]. Expert Rev Vaccines, 2021, 20(5): 487- a regulatory hub that tunes multiple dsRNA-sensing pathways[J].
495. Int Immunol, 2023, 35(3): 123-133.
[55] Yu DL, Zheng SP, Sui LN, et al. The role of AIM2 in inflam- [63] Zhang T, Yin CR, Fedorov A, et al. ADAR1 masks the cancer
mation and tumors[J]. Front Immunol, 2024, 15: 1466440. immunotherapeutic promise of ZBP1-driven necroptosis[J]. Na-
[56] Kloor M, Reuschenbach M, Pauligk C, et al. A frameshift pep- ture, 2022, 606(7914): 594-602.
tide neoantigen-based vaccine for mismatch repair-deficient [64] Wang S, Song A, Xie J, et al. Fn-OMV potentiates ZBP1-medi-
cancers: a phase I/IIa clinical trial[J]. Clin Cancer Res, 2020, ated PANoptosis triggered by oncolytic HSV-1 to fuel antitu-
26(17): 4503-4510. mor immunity[J]. Nat Commun, 2024, 15(1): 3669.
[57] Romero MF, Krall JB, Nichols PJ, et al. Novel Z-DNA binding [65] Goswami A, Goyal S, Singh K, et al. Abstract 6898: Identifica-
domains in giant viruses[J]. J Biol Chem, 2024, 300(8): 107504. tion of a novel first-in-class inhibitor targeting the ADAR1 p150
[58] Athanasiadis A. Zalpha-domains: at the intersection between isoform demonstrates robust anti-tumor efficacy in a syngeneic
RNA editing and innate immunity[J]. Semin Cell Dev Biol, mouse model[J]. Cancer Res, 2025, 85(8_Supplement_1): 6898.

［
专家介绍］尤启冬，中国药科大学药学院教授，博士生导师。国家“万人计划”教学名师，国家教
学名师。获国家科技进步奖二等奖，教育部霍英东优秀青年教师奖、江苏省“五一劳动奖章”等。
担任国家药典委员会顾问委员；中国药学会理事；江苏省药学会副秘书长、常务理事、药物化学专
业委员会主任委员。担任《中国药科大学学报》常务副主编。

专家介绍］徐晓莉，中国药科大学教授，博士生导师；主要研究方向是针对核酸免疫系统和分子
［
伴侣系统进行新药分子设计与发现研究。相关工作发表在 J Med Chem、Cell Chem Bio、 Acta
Pharm Sin B 等期刊上，申请及授权专利 20 余项，主持国家自然科学基金项目 5 项，获得江苏省优
秀青年基金项目支持，入选江苏省“青蓝工程”青年骨干教师以及第 22 届中国药学会-施维雅青年
药物化学奖。Molecules 期刊客座编辑，《中国药科大学学报》、《中国药物化学杂志》青年编委。